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Abstract
Background: The development and progression of hepatocellular carcinoma (HCC) is significantly correlated to the
accumulation of genomic alterations. Array-based comparative genomic hybridization (array CGH) has been applied to a
wide range of tumors including HCCs for the genome-wide high resolution screening of DNA copy number changes.
However, the relevant chromosomal variations that play a central role in the development of HCC still are not fully
elucidated.
Methods: In present study, in order to further characterize the copy number alterations (CNAs) important to HCC
development, we conducted a meta-analysis of four published independent array-CGH datasets including total 159
samples.
Results: Eighty five significant gains (frequency $25%) were mostly mapped to five broad chromosomal regions including
1q, 6p, 8q, 17q and 20p, as well as two narrow regions 5p15.33 and 9q34.2-34.3. Eighty eight significant losses (frequency
$25%) were most frequently present in 4q, 6q, 8p, 9p, 13q, 14q, 16q, and 17p. Significant correlations existed between
chromosomal aberrations either located on the same chromosome or the different chromosomes. HCCs with different
etiologies largely exhibited surprisingly similar profiles of chromosomal aberrations with only a few exceptions.
Furthermore, the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis indicated that the genes affected by
these chromosomal aberrations were significantly enriched in 31 canonical pathways with the highest enrichment observed
for antiviral immunity pathways.
Conclusions: Taken together, our findings provide novel and important clues for the implications of antiviral immunity-
related gene pathways in the pathogenesis and progression of HCC.
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Introduction
The development and progression of hepatocellular carcinoma
(HCC) is significantly correlated to the accumulation of genomic
alterations [1]. Therefore, it is important to have a clear landscape
of the genomic aberrations that occur during the multistep process
of hepatocarcinogenesis. Previous studies have used high-resolution
molecular karyotyping analyses to provide a comprehensive catalog
of structural aberrations of the whole chromosomes in HCC [2].
However, this method is highly specialized and time-consuming. As
a consequence, only a very limited number of HCC cases have been
evaluated in these studies. Moreover, the modest resolution of the
karyotyping analysis made it difficult to fully define the overall
genomic profiles of HCC in a more accurate manner. Comparative
genomic hybridization (CGH) has been developedin recent years to
monitor the DNA copy number changes at a global level [3].
However, traditional CGH techniques still have the limitation of
modest resolution (approximately 2 Mb for amplifications and 10–
20 Mb for deletions) and thus could not detect changes in smaller
chromosomal regions [4]. In comparison, array-based CGH (array
CGH) is a newly developed technology that allows for high-
throughput and high-resolution (at 1 Mb) screening of genome-
wide DNA copy number changes (either amplifications or deletions)
at the gene level [5]. Array CGH combines fluorescence techniques
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12with the microarray platform that allows for the comparison of
DNA content in two differentially labeled genomes: a test genome
(patient)and a referencegenome(control).Themicroarray platform
also allows for the simultaneous scanning of thousands of individual
DNA sequences from the whole genome, and provides high-
resolution data on the locations of identified aberrations in a single
experiment. To date, array-CGH has been applied to a wide range
of solid tumors, including liver, breast, gastric, kidney and bladder
cancers [6,7,8,9,10]. Recently, another technology platform based
on single nucleotide polymorphism (SNP) array has been developed
to determine the copy number abnormalities of genomic DNA at
sub-kilobase resolution [11,12]. Except for an advantage of high
resolution, this platform also has a limitation of high signal-to-noise
ratio which is hard to improve[13].
Many investigators have made varying attempts to search for
genes implicated in hepatocarcinogenesis. Screening for chromo-
somal regions with frequent gains and losses is one of the first steps
toward the identification of genes. Using the traditional and array-
CGH, frequent DNA copy number gains at chromosomes 1q, 8q
and 20q, and frequent DNA copy number losses at 1p, 4q, 8p,
13q, 16q and 17p have been identified in HCC samples
[6,14,15,16,17,18,19]. Some of these regions contain known
candidate oncogenes or tumor suppressor genes, such as
ZNF217 (20q13) [20], TP53 (17p13), RB1 (13q14) [21]and cyclin
D1 (11q13) [22]. However, it is believed that the currently
identified genes represented only a small percentage of causal
elements in hepatocarcinogenesis and the vast majority of genes
with chromosomal aberrations that may play a central role in
HCC development are still unknown.
Meta-analysis is a systematic and quantitative synthesis of prior
evidence [23]. It offers the opportunity to critically evaluate and
statistically combine the results of comparable studies or trials in
order to achieve more robust and reliable results as well as identify
novel findings that are not apparent in individual studies. In
previous reports, a meta-analysis of CGH data comprising of 785
HCCs has been carried out and identified significant correlations of
chromosomal deletions on 4q, 13q, and 16q with hepatitis B virus
(HBV) etiology [24]. Recently, using the array-CGH technology,
several different studies have generated a wealth of data on more
than 100 analyzed HCC samples that await a more comprehensive
interpretation [16,25,26,27]. The aim of this study was to identify
potential genes and pathways important to HCC by utilizing the
available data from published array CGH studies of human HCC.
Materials and Methods
Data collection of array CGH studies in HCC
Datasets for HCC array CGH studies were identified from
public resources including the supplementary files of published
papers, NCBI Gene Expression Omnibus (GEO, http://www.
ncbi.nlm.nih.gov/geo), ArrayExpress (http://www.ebi.ac.uk) da-
tabase using hepatocellular carcinoma and array-based compar-
ative genomic hybridization as keywords. Datasets from studies
using HCC cell lines were excluded. We identified four datasets
with complete original data that are publicly available, including
two from the supplementary files of published HCC array CGH
studies and two from the GEO database (GSE8351 and
GSE22635) [16,25,26,27]. The detailed information was listed in
Table 1. Three of the four studies used BAC clone as the
hybridization probe while one used synthetic oligonucleotides as
the hybridization probe. A total of 159 HCC tissue samples in
these four datasets were collected, including 54 samples with HBV
infection, 57 with hepatitis C virus (HCV) infection, 6 with the
infections of both HBV and HCV, 3 with positive hepatitis B virus
X protein (HBx), and 39 samples without viral infection.
Data pre-processing for the integration across different
platforms
Because the four array CGH datasets in this study were
generated using different types of technical platforms that contain
different numbers of probes at varied spacing and resolution, they
cannot be directly compared and combined. To transform the
datasets from different platforms into a common format for the
purpose of meta-analysis, we pre-processed the original dataset of
each study based on a procedure previously described with minor
modification [24,28]. The detailed procedure used in this study is
described below:
First step: reconciliation of genome mapping data
generated from BAC clones and oligonucleotide
probes. In the original datasets, chromosomal positions of
BAC and oligo probes were assigned based on the different
versions of human genome assembly, such as hg15, hg17 and
hg18. Therefore, we used the annotation database of UCSC
human genome (hg19/GRCh37) to re-assign the start and end
chromosomal positions for all BAC and oligo probes from the four
datasets. The unmappable probes were excluded from further
analysis.
Second step: assignment of chromosomal positioning
anchors. Because the copy number alterations (CNAs) of
chromosomal segments were detected on different scales by
different probes in the four datasets, it was difficult to directly
compare and integrate these datasets. To resolve this issue, we
assigned a set of chromosomal positioning anchors that were
composed of the start and end chromosomal positions of all the
probes used in the four datasets. The log2-transformed DNA copy
number ratio for each anchor was then determined for all the
samples from different datasets based on the following principles.
Table 1. Information of 4 collected public datasets (n=159).
ID References Platform Etiology, N
All HBV HCV HBV/HCV HBx non-viral
1 Mohini A.Patil et al.(2005) BAC 44 34 3 — — 7
2 Yasuyo Chochi et al.(2009) BAC 42 6* 34* 2* — —
3 Christof Schlaeger et al.(2008) BAC 63 11 14 4 3 31
4 Kazuya Taniguchi et al.(2010) Oligo 10 3 6 — — 1
Total 159 54 57 6 3 39
*Information of virus infection for individual samples is unavailable. HBV, hepatitis B virus; HCV, hepatitis C virus; HBx, hepatitis B virus X protein.
doi:10.1371/journal.pone.0028404.t001
Array CGH Meta-Analysis in HCC
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log2-transformed ratio for probe was assigned to corresponding
anchors. When an anchor lied outside of any detected probes of
the dataset, a missing value was created and set to the anchor.
Using this approach, we were able to delineate the same
chromosomal positions to the different probes used in the
different datasets of the four studies.
Third step: scaling and segmentation across multiple
platforms. To integrate data across multiple sources for meta-
analysis, multi-platform segmentation with proper scaling was
performed by using a multi-platform circular binary segmentation
(MPCBS) algorithm recently reported by Zhang et al [28], which
was implemented into an R package which can be accessed on R-
Forge undera projectname MPCBS(http://r-forge.r-project.org/).
This algorithm, which is based on a simple multi-platform change-
point model, relies on a weighted sum of t-statistics to scan for copy
number changes and does not require a pre-standardization of
different data sources. To minimize the computational complexity
and maximize the generality, chromosomes were segmented
individually and sex chromosomes were not included.
Fourth step: determination of gain and loss events. After
segmentation, the CNAs of chromosomal segments were
determined using a nonhierarchical k-means clustering (k=3)
algorithm [29]. All log2-transformed ratio values of the segments
generated in the third step were clustered and classified into three
subgroups bytwothresholdvalues(0.141and20.136),representing
copy number gain (.0.141), copy number loss (,20.136), and no
copy number change (between 20.136 and 0.141).
Fifth step: evaluation of pre-processing perfor-
mance. Pearson Correlation Coefficient (PCC) analysis was used
to evaluate the performance of pre-processing. We first calculated the
PCC value of log2-transformed ratio between any two samples from
the same datasets. Then we estimated the correlation among samples
of different platforms before and after pre-processing. The PCC
values of any two samples should not show the dependencies on the
platform after high-quality preprocessing.
Profiling of chromosomal aberrations and pathway
analysis
Based on the definition of gain and loss events, we conducted
genome-wide profiling of CNAs for all the HCC samples included
in the four datasets and calculated the frequencies of chromosomal
aberrations for each sample. We then, using a Chi-square test,
compared the frequencies of copy number gains and losses
separately between HBV-HCC and HCV-HCC, or between
HCC with and without viral infection. In further analyses, we only
focused on those highly prevalent events of copy number gains and
losses (frequency .25%). We first evaluated the correlation
between any two CNAs by calculating the PCC value. Then,
the genes in these segments with frequent gains/losses were
mapped into the pathways derived from the Kyoto Encyclopedia
of Genes and Genomes (KEGG) database [30]. The pathways that
were significantly affected by the identified CNAs were determined
by Fisher’ exact test.
Results
Profile of chromosomal alterations in all HCC samples
We profiled the CNAs (gains or losses) of chromosomal
segments in human HCC through a meta-analysis of four
available independent array CGH datasets including total 159
samples. To integrate all datasets from different platforms, the raw
data were pre-processed and the pre-processing performance was
evaluated using the PCC analysis. Our results indicated that the
PCC values of individual samples within a platform were
significantly higher than those between two different platforms
before data pre-processing. After pre-processing, the correlation
obtained for samples between different platforms after pre-
processing was significantly improved with an increase of average
correlation coefficient from 0.198 to 0.349 (Fig. 1). These data
showed that the four independent datasets have been successfully
transformed into a comparable form. Next, chromosomal gain and
Figure 1. Comparison of correlations among log2-transformed ratios of 159 samples from four independent datasets before (a)
and after preprocessing (b). In triangle (a) and (b), color points dotted in rectangles represent PCC values of log2-transformed ratio between any
two samples from different datasets, while color points dotted in small triangles represent those from same dataset. The brightness of color blue is
directly proportional to the value (0 – 1) of Pearson correlation coefficient.
doi:10.1371/journal.pone.0028404.g001
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olds of 0.141 and -0.136 derived from the k-means clustering
analysis and the frequencies of chromosomal aberrations were
calculated for all HCC samples. Our results indicated that 85
chromosomal segments exhibited a frequent copy number gain
($25%) and 88 exhibited a frequent copy number loss ($25%).
Detailed data was not presented here because of the space
limitation. They are available when required. As shown in Fig. 2,
the significant gains were mostly mapped to several broad
chromosomal regions including 1q, 6p, 8q, 17q and 20q, as well
as four narrow regions including 5p15.33- 5p14.2, 9q34.2-34.3,
20p13 and 20p11.21. Significant losses were frequently observed
in 4q, 6q, 8p, 9p, 13q, 14q, 16q, and 17p. Among these regions,
chromosome 1q was most significantly affected by copy number
gain and chromosome 8p was most significantly affected by copy
number loss. In particular, gains in 1q32.1, 1q24.1, and 1q21.3-
23.3 were detected in .70% of all HCC samples, and losses in
8p23.3-21.3 were detected in .55% of the samples.
Correlations between significant chromosomal
aberrations
Spearman’s rank correlation coefficient was calculated to assess
the correlations between different chromosomal copy number
gains and losses described above at the significant level of
p,0.001. Our results indicated that significant correlations existed
between specific chromosomal aberrations either located on the
same or different chromosomes and the significances from the
same chromosome were usually higher than those from different
chromosomes. As shown in Fig. 3(a), significant finding from the
same chromosome were mainly identified for chromosomes 1q,
4q, 5p, 6p, 6q, 8p, 8q, 9p, 13q, 14q, 16q, 17p, 17q, 20p, 20q and
between 6p and 6q, 8p and 8q, 17p and 17q, 20p and 20q. As
indicated in Fig. 3(b), significant correlations mainly existed
between 1q gains and 5p gains, and 6p gains or 4q losses, with a
positive correlation coefficient of at least 0.25, 20q gains and 9p
losses or 14q losses with a negative correlation coefficient of over
20.3. In addition, losses of 4q, 9p, 13q, 16q and 17p frequently
co-occurred with a correlation coefficient ranging from 0.26 to
0.46. Significant correlations were also observed between 6p gains
and 8p losses, 8p losses and 9p losses, and 14q losses and 16q
losses.
Canonical pathways significantly linked with
chromosomal aberrations
To explore the potential effects of chromosomal aberrations
implicated in the molecular mechanism of HCC development, we
further analyzed the functional KEGG pathways enriched with
genes located on the chromosomal segments with significant copy
number alterations. Our results indicated that the genes affected
by chromosomal aberrations were significantly enriched in 31
canonical pathways. The list of pathways together with the related
gene information was summarized in Table 2. According to the
Figure 2. Profile of chromosomal alterations in all HCC samples (n=159). (a), heatmap of CNAs across all chromosomes. (b), the
frequencies of CNAs across all chromosomes. Copy number gain and loss events of chromosomal segments were determined using log2-transformed
ratio thresholds of 0.141 and 20.136 derived from the k-means clustering analysis. The color brightness is directly proportional to the frequency of
CNA. Color red represents copy number gain and color blue represents copy number loss. CNA: copy number alteration.
doi:10.1371/journal.pone.0028404.g002
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categories: 18 immune-related pathways, 3 cancer-related path-
ways and 10 metabolism-related pathways. Among these path-
ways, antiviral immunity pathways were most significantly
affected, such as the antigen processing and presentation pathway
(hsa04612), RIG I like receptor signaling pathway (hsa04622),
natural killer cell mediated cytotoxicity pathway (hsa04650),
cytosolic DNA sensing pathway (hsa04623), toll like receptor
signaling pathway (hsa04620), and cytokine and cytokine receptor
interaction pathway (hsa04060). Moreover, we found many
pathways were interrelated and driven by the presence of same
or similar sets of genes. For example, seven immune-related
pathways (hsa05320, hsa04612, hsa04622, hsa04650, hsa04623,
hsa04620 and hsa04140) were driven by signals in the same core
set of the interferon-alpha family genes (IFNA1, IFNA10, IFNA13,
IFNA14, IFNA16, IFNA17, IFNA2, IFNA21, IFNA4, IFNA5, IFNA6,
IFNA7, IFNA8) that are contiguously located within a 0.3 Mb
region on chromosome 9p21.3. These genes play a vital role in the
non-specific antiviral immunity that occurs at the early phase of
viral infections. We also found that 10 immune-related pathways
harbored another core set of genes, the human leukocyte antigen
gene family [27]. In addition, six metabolism-related pathway
(hsa00982, hsa00140, hsa00053, hsa00983, hsa00980, hsa00040)
had the same core set of genes, the uridine diphosphate
glycosyltransferase 2 family (UGT2A1, UGT2A3, UGT2B4,
UGT2B7, UGT2B10, UGT2B11, UGT2B15, UGT2B17,
UGT2B28), that are contiguously located within a 2 Mb region
on chromosome 4q13.2. Only a few cancer-related pathways were
found to be significantly affected by the chromosomal aberrations
identified in this study with a common gene set. However, several
oncogenes and tumor suppressor genes are mapped to these
pathways, such as TP53, RB1, and MYC, which have been shown
to play an important role in hepatocarcinogenesis [21,31].
Etiology-related chromosomal aberrations
We investigated the profiles of etiology-related chromosomal
aberrations in HCCs. As indicated in Fig. 4, HCC samples with
different etiologies exhibited very similar profiles of chromosomal
aberrations with only a few exceptions. When we compared the
profiles of 48 HBV-related and 23 HCV-related HCCs, 14 copy
number gains and 59 losses had significantly different frequencies.
Almost all of these segmental gains and losses were harbored in
HBV-related HCCs, except for gains of 12p13.1-12p12.3 and
losses of 3q26.1-3q26.2 and 3q26.2-3q26.33 that appeared in
HCV-related HCCs with significantly higher frequencies. The
significant copy number gains and losses in HBV-related HCCs
were most commonly located on chromosomal region 10p, and
14q and 4q, respectively. We also performed the comparison of
chromosomal aberration profiles between virus-related HCCs and
non-virus-related HCCs, and identified 27 gains and 17 losses
showing a significant difference in frequencies. All significant losses
were present in virus-related HCCs and most were located on
chromosomal region 16q. In comparison, significant gains were
mostly located on chromosomal regions 2p and 4p in virus-related
HCCs, whereas chromosomal regions 8p and 10p in non-virus-
related HCCs.
Discussion
Meta-analysis of array CGH is valued as an integrated
approach to simultaneously analyze information from different
studies for the detection of chromosome aberrations with
enhanced resolution and accuracy. A recent study has successfully
performed a meta-analysis of array CGH data derived from a
series of primary cancers to cluster tumor type by CNAs [24]. In
this study, we, for the first time, conducted a cross-platform meta-
analysis of HCC array CGH data obtained from different studies.
Figure 3. Correlations between significant chromosomal aberrations either located on the same (a) or different (b) chromosomes in
all HCCs. Chromosomal segments with significant gain were highlighted in red and those with significant loss in blue. Spearman’s rank correlation
coefficient was calculated to assess the correlations between different chromosomal copy number gains and losses at the significant level of
p,0.001.
doi:10.1371/journal.pone.0028404.g003
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original data based on the MPCBS statistical algorithm and
demonstrated that this data pre-processing exhibited an optimum
performance on multi-platform integration.
In the present study, our meta-analysis identified 85 significant
chromosomal gains and 88 losses. The majority of these significant
aberrations were consistent with previous reports using conven-
tional CGH approaches or including smaller sample size. In
addition, our study identified several aberrations located in very
narrow chromosomal regions, such as copy number gains on
5p15.33-5p14.2, 9q34.2-9q34.3 or 20p13-20p11.21 and copy
number loss on 9p24.3-9p21.1 or 14q. The 5p15.33 regions
contains hTERT gene, which encodes the catalytic subunit of
telomerase, a critical component in telomere regulation. In an
array CGH study, Yasuyo et al. [16] have reported that the gain of
5p15.33 was detected in 50% of HCC samples. Gain of this region
has also been reported to be associated with progression of bladder
cancer [32]. The 5p15.2 region hosts the potential target gene,
delta catenin (CTNND2), over-expressed in prostate cancer [33].
The chromosomal region 9p24.3 harbors three putative tumor
suppressor genes, DMRT1, DMRT3 and DOCK8. A recent study
has reported the frequent deletion of this region in squamous cell
carcinoma of the lung [34]. Furthermore, our results indicated
that significant correlations existed between chromosomal aber-
rations either located on the same chromosome or the different
chromosomes, suggesting that these aberrations might appear non-
randomly. It remains to be further elucidated whether there are
sequential correlations among the occurrence of these genomic
aberrations in the development and progression of HCC.
We also compared genomic aberrations between HCCs with
different etiologies and observed two noteworthy findings. First,
our study found that HCCs with different etiologies exhibited very
Table 2. The functional KEGG pathways enriched with genes located on the chromosomal segments with significant CNAs in all
HCCs.
Pathway KEGG ID
Mapped gene number/
Pathway gene number P value
SYSTEMIC_LUPUS ERYTHEMATOSUS hsa05322 94/140 ,1.00E-13
AUTOIMMUNE THYROID DISEASE hsa05320 38/53 1.57E-12
ANTIGEN PROCESSING AND PRESENTATION hsa04612 48/89 1.52E-08
ALLOGRAFT REJECTION hsa05330 23/38 2.78E-06
VIRAL MYOCARDITIS hsa05416 37/73 3.85E-06
RIG I LIKE RECEPTOR SIGNALING PATHWAY hsa04622 36/71 4.97E-06
NATURAL KILLER CELL MEDIATED CYTOTOXICITY hsa04650 60/137 5.55E-06
ASTHMA hsa05310 18/30 2.91E-05
CYTOSOLIC DNA SENSING PATHWAY hsa04623 28/56 5.97E-05
TYPE I DIABETES MELLITUS hsa04940 23/44 8.76E-05
LEISHMANIA INFECTION hsa05140 33/72 1.58E-04
TOLL LIKE RECEPTOR SIGNALING PATHWAY hsa04620 43/102 2.56E-04
GRAFT VERSUS HOST DISEASE hsa05332 21/42 3.70E-04
REGULATION OF AUTOPHAGY hsa04140 17/35 0.002
COMPLEMENT AND COAGULATION CASCADES hsa04610 29/69 0.002
DRUG METABOLISM CYTOCHROME P450 hsa00982 29/72 0.004
STEROID HORMONE BIOSYNTHESIS hsa00140 22/55 0.011
CYTOKINE CYTOKINE RECEPTOR INTERACTION hsa04060 87/267 0.014
INTESTINAL IMMUNE NETWORK FOR IGA PRODUCTION hsa04672 19/48 0.018
ASCORBATE AND ALDARATE METABOLISM hsa00053 11/25 0.019
CELL ADHESION MOLECULES CAMS hsa04514 46/134 0.021
NITROGEN METABOLISM hsa00910 10/23 0.025
PROXIMAL TUBULE BICARBONATE RECLAMATION hsa04964 10/23 0.025
SMALL CELL LUNG CANCER hsa05222 30/84 0.027
AMYOTROPHIC LATERAL SCLEROSIS ALS hsa05014 20/53 0.028
DRUG METABOLISM OTHER ENZYMES hsa00983 19/51 0.036
METABOLISM OF XENOBIOTICS BY CYTOCHROME P450 hsa00980 25/70 0.037
BLADDER CANCER hsa05219 16/42 0.037
RIBOFLAVIN METABOLISM hsa00740 7/16 0.040
BIOSYNTHESIS OF UNSATURATED FATTY ACIDS hsa01040 9/22 0.046
PENTOSE AND GLUCURONATE INTERCONVERSIONS hsa00040 11/28 0.048
Note: The pathways that were significantly affected by the identfied CNAs were determined by Fisher’ exact test.
KEGG, Kyoto Encyclopedia of Genes and Genomes; CNA, copy number alteration.
doi:10.1371/journal.pone.0028404.t002
Array CGH Meta-Analysis in HCC
PLoS ONE | www.plosone.org 6 December 2011 | Volume 6 | Issue 12 | e28404similar profiles of chromosomal aberrations. Second, we found
that chromosomal aberrations appeared more frequently in HBV-
HCCs than in HCV-HCCs, and in virus-related HCCs than in
non-virus-related HCCs. These findings suggest that virus
infection, especially HBV infection, may play a major role in
hepatocarcinogenesis by causing chromosomal aberrations. In our
analyses, we observed that the significant copy number gains were
most commonly located on chromosomal region 10p and
significant losses on 14q and 4q in HBV-related HCCs. Yeh et
al. have reported that allelic loss at chromosome 4q21-23 occurs
frequently in human hepatocellular carcinoma [35]. Fas-associated
phosphatase-1 (FAP-1) gene, a potential candidate TSG, is located
in this region. Another study has demonstrated that three regions
at 14q exhibit the frequent loss of heterozygosity in head and neck
squamous cell carcinoma. Several candidate TSGs such as
CHES1, BMP4, SAV, and PNN exist in these region [36]. These
TSGs may play critical roles in hepatocarcinogenesis. Previous
CGH studies have also analyzed the CNA profiles of HCCs with
HBV or HCV infection. One study has reported that the
amplification of 11q13, which corresponds to the chromosomal
region harboring the genes for cyclin D1 and hst-1, is frequently
observed in HBV-positive HCCs. In contrast, loss of 10q has been
detected exclusively in HCV-positive HCCs [14]. Another study
has demonstrated that a single high level amplification is only seen
on 5q21 in HBV-related HCCs [37]. In addition, Christof
Schlaeger et al compared HBV- and HCV-associated HCCs by
array CGH, and observed that major differences in the
frequencies of gains were at 1q32.1, 7q22.1, 10q26.3-qter in
Figure 4. Profiles of etiology-related chromosomal aberrations in HCCs. (a). the comparison of chromosomal aberration profiles between
HBV-related HCCs and HCV-related HCCs. (b), the comparison of chromosomal aberration profiles between virus-related HCCs and non-virus-related
HCCs. Copy number gains and losses with a significant difference in frequencies were highlighted in red and blue, respectively.
doi:10.1371/journal.pone.0028404.g004
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14q21.2-32.33 were more significant in HBV–positive tumors
[27]. The inconsistency among these results is possibly due to the
different technology platforms and sample selection. Further
validation using large sample size is warranted.
The tumorigenesis of HCC is a multi-step and multi-factorial
process. Many attempts have been made to identify the abnormal
pathways underlying hepatocarcinogenesis. Epidermal growth
factor (EGF) signaling pathway is one of the most thoroughly
evaluated signaling cascades in human HCC [38]. Genetic
evidence has been also provided by a recent study showing gains
of chromosome 7 in human HCC, where EGFR is located. A series
of studies have also found the dysregulation of pathways involved
in cellular differentiation and proliferation in HCC, such as the
WNT canonical pathway and the Hedgehog signaling pathway
(HH) [39,40,41,42]. Interestingly, the most noteworthy finding of
this study is that the genes affected by chromosomal aberrations in
HCC were most significantly enriched in antiviral immunity
pathways, followed by the cancer-related pathways and metabo-
lism-related pathways. This is highly biologically plausible, given
the important functions of immunity pathways in the response to
viral infection and chronic inflammation [43]. Previous studies
have provided various lines of experimental evidence in accor-
dance with our findings. For example, Kirsten et al. have reported
a significant amplification of 6p21.3 that corresponds to the HLA-
region in ovarian cancer [44]. In addition, somatic deletions in
chromosomes 9 and 22 have been studied in 21 paired HCC and
adjacent tumor-free liver tissue samples [45]. Among informative
HCC cases, the highest rates of loss of heterozygosis (LOH) were
observed for 9p21 (40% or 4/10 at IFNA) and 9q23 (23% or 3/13
at D9S318). Clinical data indicate that chromosome 9p21
deletions occurred preferentially in larger tumors (.5c m
diameter). Another study has also reported that LOH on IFN-
alpha locus at 9p21 is a prognostic indicator of bacillus Calmette-
Guerin response for non-muscle invasive bladder cancer [46].
Similarly, Roman et al. [47] has investigated the chromosomal
aberrations in head and neck squamous cell carcinomas by array
CGH and found that the genes involved in cytokine-cytokine
receptor interaction pathway were the largest group of genes (23/
149) showing chromosomal gains. The copy number of several
interleukin genes (IL10, IL19, IL20 and IL24) mapped to1q32 have
been significantly increased and all these genes were previously
found to be associated with the development of HNSCCs. In
addition to the interleukins at 1q32, there were amplified genes
from other regions of the genome, such as CCL26, EGFR, IL17R,
IL28A, IL29, IL2RB, IL12RB1, VEGF, XCL2, TNFSF9 and CD40.
Taken together, these lines of evidence strongly suggest that the
functional aberration of antiviral immunity pathways may be
significantly involved in the development and progression of HCC.
In summary, we conducted a cross-platform meta-analysis of
HCC array CGH data. We identified multiple chromosome
regions with significant aberrations in genes enriched in antiviral
immunity pathways. Our results provide a sketchy description of
the genomic alterations in HCCs and generate further testable
hypotheses that the deficiency of antiviral immunity pathways may
play key roles in hepatocarcinogenesis.
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